Hybio Pharmaceutical (300199) — Working Capital to Net Assets Ratio
Hybio Pharmaceutical (300199) has a Working Capital to Net Assets ratio of -142.9% as of September 2025. Working capital of CN¥-951.59 Million (current assets of CN¥565.09 Million minus current liabilities of CN¥1.52 Billion) is measured against net assets of CN¥666.08 Million. A higher ratio indicates strong short-term liquidity financed by the equity base. See defensive interval ratio of Hybio Pharmaceutical to measure how many days the company can operate on defensive assets alone.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Hybio Pharmaceutical Working Capital to Net Assets (2007–2024)
This chart shows how Hybio Pharmaceutical's Working Capital to Net Assets ratio has evolved across 18 annual periods from 2007 to 2024. As of September 2025, the ratio stands at -142.9%, reflecting working capital of CN¥-951.59 Million against net assets of CN¥666.08 Million CNY. For the complete balance sheet picture, see balance sheet size of Hybio Pharmaceutical.
Annual Working Capital to Net Assets for Hybio Pharmaceutical (2007–2024)
The table below presents the year-by-year Working Capital to Net Assets ratio for Hybio Pharmaceutical from 2007 to 2024, covering 18 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. Check financial resilience of Hybio Pharmaceutical to evaluate the company's liquid asset resilience ratio.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2024 | -161.0% | CN¥-961.51 Million | CN¥597.05 Million | CN¥463.05 Million | CN¥1.42 Billion | ▼ -66.6 pp |
| 2023 | -94.5% | CN¥-739.80 Million | CN¥783.21 Million | CN¥683.64 Million | CN¥1.42 Billion | ▼ -68.6 pp |
| 2022 | -25.9% | CN¥-335.63 Million | CN¥1.30 Billion | CN¥812.32 Million | CN¥1.15 Billion | ▼ -50.8 pp |
| 2021 | 25.0% | CN¥411.26 Million | CN¥1.65 Billion | CN¥1.16 Billion | CN¥743.82 Million | ▲ +27.9 pp |
| 2020 | -3.0% | CN¥-49.98 Million | CN¥1.68 Billion | CN¥1.05 Billion | CN¥1.10 Billion | ▼ -36.9 pp |
| 2019 | 33.9% | CN¥757.06 Million | CN¥2.23 Billion | CN¥1.89 Billion | CN¥1.14 Billion | ▼ -30.7 pp |
| 2018 | 64.6% | CN¥2.19 Billion | CN¥3.39 Billion | CN¥3.02 Billion | CN¥831.93 Million | ▲ +19.9 pp |
| 2017 | 44.6% | CN¥1.73 Billion | CN¥3.88 Billion | CN¥2.60 Billion | CN¥865.01 Million | ▲ +2.7 pp |
| 2016 | 41.9% | CN¥1.51 Billion | CN¥3.60 Billion | CN¥1.84 Billion | CN¥330.92 Million | ▲ +20.7 pp |
| 2015 | 21.2% | CN¥560.29 Million | CN¥2.64 Billion | CN¥979.38 Million | CN¥419.09 Million | ▼ -46.1 pp |
| 2014 | 67.3% | CN¥872.52 Million | CN¥1.30 Billion | CN¥990.66 Million | CN¥118.14 Million | ▲ +14.8 pp |
| 2013 | 52.6% | CN¥590.81 Million | CN¥1.12 Billion | CN¥667.20 Million | CN¥76.39 Million | ▼ -20.3 pp |
| 2012 | 72.9% | CN¥740.44 Million | CN¥1.02 Billion | CN¥789.94 Million | CN¥49.50 Million | ▼ -19.1 pp |
| 2011 | 92.0% | CN¥898.16 Million | CN¥976.09 Million | CN¥927.75 Million | CN¥29.59 Million | ▲ +27.0 pp |
| 2010 | 65.0% | CN¥117.40 Million | CN¥180.59 Million | CN¥133.10 Million | CN¥15.71 Million | ▲ +19.4 pp |
| 2009 | 45.6% | CN¥58.31 Million | CN¥127.74 Million | CN¥112.62 Million | CN¥54.31 Million | ▲ +13.1 pp |
| 2008 | 32.5% | CN¥32.30 Million | CN¥99.23 Million | CN¥69.41 Million | CN¥37.11 Million | ▼ -24.5 pp |
| 2007 | 57.1% | CN¥27.79 Million | CN¥48.70 Million | CN¥37.34 Million | CN¥9.54 Million | — |